Notch Signaling Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Notch signaling pathway is a highly conserved cell-cell communication system that plays critical roles in neural development, synaptic plasticity, and cellular differentiation. In neurodegeneration, Notch signaling intersects with multiple pathological processes including amyloid-β toxicity, neuroinflammation, and vascular dysfunction. This pathway represents both a therapeutic target and a modulator of disease progression in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and CADASIL.
flowchart TD
A[Notch Ligands<br>DLL1/3/4, JAG1/2] --> B[Notch Receptor<br>NOTCH1-4] -->
B --> C[ADAM10 Cleavage<br>S2 Site] -->
C --> D[γ-Secretase Cleavage<br>S3 Site] -->
D --> E[NICD Release] -->
E --> F[Nuclear Translocation] -->
F --> G[CSL/RBPJ Binding] -->
G --> H[Coactivator Recruitment<br>MAML, p300] -->
H --> I[Target Gene Transcription<br>Hes1, Hes5, Hey1/2] -->
I --> J1[Neuronal Differentiation] -->
I --> J2[Synaptic Plasticity)
I --> J3[Glial Cell Fate] -->
I --> J4[Gene Expression Regulation] -->
K[Aβ Oligomers] -.->|Inhibit| B
L[α-Synuclein] -.->|Dysregulate| B
M[TDP-43) -.->|Alter| G
| Protein |
Gene |
Function |
Neurodegeneration Relevance |
| NOTCH1 |
NOTCH1 |
Canonical Notch receptor |
AD: Aβ interaction, memory impairment |
| NOTCH2 |
NOTCH2 |
Canonical Notch receptor |
AD: Synaptic plasticity deficits |
| NOTCH3 |
NOTCH3 |
Vascular Notch receptor |
CADASIL: Mutations cause vascular dysfunction |
| NOTCH4 |
NOTCH4 |
Canonical Notch receptor |
AD: Angiogenesis regulation |
| DLL1 |
DLL1 |
Delta-like ligand 1 |
Neuronal differentiation |
| DLL3 |
DLL3 |
Delta-like ligand 3 |
ALS: Aberrant expression |
| DLL4 |
DLL4 |
Delta-like ligand 4 |
Vascular development |
| JAG1 |
JAG1 |
Jagged ligand 1 |
Neurogenesis |
| JAG2 |
JAG2 |
Jagged ligand 2 |
Glial differentiation |
| ADAM10 |
ADAM10 |
α-Secretase |
AD: Reduced activity, Aβ production |
| PSEN1 |
PSEN1 |
γ-Secretase component |
AD: Mutations increase Aβ42 |
| PSEN2 |
PSEN2 |
γ-Secretase component |
AD: Mutations increase Aβ42 |
| RBPJ |
RBPJ |
CSL transcription factor |
Canonical pathway mediator |
| NICD |
— |
Notch intracellular domain |
Nuclear signaling molecule |
| Hes1 |
HES1 |
Transcriptional repressor |
Neuronal differentiation |
| Hes5 |
HES5 |
Transcriptional repressor |
Neuronal differentiation |
| Hey1 |
HEY1 |
Transcriptional repressor |
Notch target |
| Hey2 |
HEY2 |
Transcriptional repressor |
Notch target |
Amyloid-β oligomers directly interact with Notch receptors, disrupting normal Notch signaling:
- Receptor cleavage inhibition: Aβ interferes with ADAM10-mediated S2 cleavage, altering Notch processing
- Transcriptional dysregulation: Aβ reduces NICD nuclear translocation, impairing Notch target gene expression
- Synaptic plasticity: Notch-Hes1 signaling is required for long-term potentiation (LTP); Aβ-mediated Notch disruption contributes to synaptic failure
ADAM10 (also known as α-secretase) is responsible for the non-amyloidogenic processing of APP and Notch receptor cleavage:
- ADAM10 expression decreases in AD brain (Bandyopadhyay et al., 2006)
- Reduced ADAM10 promotes amyloidogenic Aβ production
- ADAM10 activity is required for Notch-dependent synaptic plasticity
γ-Secretase cleaves both APP and Notch:
- PSEN1/2 mutations cause familial AD and alter Notch cleavage
- γ-Secretase inhibitors (designed for AD) caused Notch-related side effects
- Modulators that shift Aβ production without affecting Notch are under development
| Strategy |
Agent |
Status |
Mechanism |
| γ-Secretase modulators |
E-2012 |
Preclinical |
Shift Aβ42/Aβ40 ratio without inhibiting Notch |
| ADAM10 activators |
— |
Research |
Increase non-amyloidogenic processing |
| Notch inhibitors |
RO4929097 |
Clinical (oncology) |
Block Notch-dependent transcription |
Notch signaling regulates adult neurogenesis in the subventricular zone and dentate gyrus:
- Notch activity declines with aging and PD
- Restoring Notch signaling promotes dopaminergic neuron survival in models
- α-Synuclein aggregates impair Notch-dependent transcription
Notch interacts with NF-κB and inflammatory pathways:
- Notch-NF-κB crosstalk amplifies microglial activation
- JAG1 expression on astrocytes promotes neuroinflammation
- Notch inhibition reduces glial activation in PD models
- Notch signaling enhancers: Under investigation for dopaminergic neuroprotection
- JAG1 blockade: Targeting pathological astrocyte-neuron communication
Notch signaling is altered in ALS:
- DLL3 is aberrantly expressed in ALS motor neurons (Van Hoecke et al., 2012)
- Notch hyperactivity contributes to motor neuron vulnerability
- ALS-associated TDP-43 pathology affects Notch target gene expression
TDP-43 proteinopathy (in 95% of ALS cases) intersects with Notch:
- TDP-43 binds to Notch gene promoters
- Loss of TDP-43 function disrupts Notch transcriptional regulation
- Therapeutic strategies must consider TDP-43-Notch interactions
Notch signaling patterns motor neuron pools during development:
- Proper Notch activity ensures correct motor neuron subtype specification
- Dysregulated Notch contributes to ALS phenotype
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is caused by NOTCH3 mutations:
- Mutations: Over 200 NOTCH3 mutations identified, typically cysteine substitutions in EGF-like repeats
- Vascular dysfunction: NOTCH3 critical for vascular smooth muscle cell (VSMC) maintenance
- Arteriopathy: Degeneration of VSMCs leads to vessel wall thickening, lacunar strokes, and dementia
- Granular osmiophilic material (GOM) deposits around VSMCs
- Reduced Notch3 signaling in cerebral vessels
- Small vessel disease leading to white matter lesions
| Approach |
Status |
Notes |
| γ-Secretase inhibitors |
Research |
May reduce toxic NOTCH3 signaling |
| Gene therapy |
Research |
Deliver wild-type NOTCH3 |
| Symptomatic |
Clinical |
Stroke prevention, cognitive support |
flowchart LR
A[Notch Activation] --> B[NF-κB Activation] -->
B --> C[Pro-inflammatory Cytokines<br>IL-1β, IL-6, TNF-α] -->
C --> D[Microglial Activation] -->
D --> E[Neurotoxicity] -->
F[Aβ] -.->|Amplify| B
G[α-Syn] -.->|Amplify| B
Notch interacts with key synaptic signaling pathways:
- CREB: Notch-CREB cross-talk regulates memory consolidation
- NMDA receptors: Notch modulates NMDA receptor trafficking
- Arc/Arg3.1: Notch regulates activity-dependent synaptic plasticity genes
- Notch maintains neural stem cell pools
- Notch inhibition promotes neuronal differentiation
- Impaired neurogenesis contributes to cognitive decline in AD
| Biomarker |
Source |
Relevance |
| Notch extracellular domain |
CSF |
Reflects receptor cleavage status |
| Soluble NOTCH1 |
Plasma |
AD severity marker |
| Notch target genes (Hes1, Hey1) |
Blood |
Therapeutic response |
| NOTCH3 mutations |
Genetic testing |
CADASIL diagnosis |
Rationale: Modulate Aβ production without fully inhibiting Notch
- NSAIDs: Some NSAIDs act as γ-secretase modulators
- E-2012: Developed by Eisai, shifts cleavage toward shorter Aβ peptides
Applications in neurodegeneration (primarily for cancer):
- RO4929097: γ-Secretase inhibitor (clinical trials suspended due to toxicity)
- MK-0752: Notch inhibitor (oncology)
- Increase non-amyloidogenic APP processing
- Promote Notch cleavage
- Acetyl-L-carnitine: Shown to increase ADAM10 activity
- Antisense oligonucleotides to reduce toxic NOTCH3
- γ-Secretase inhibitors to block aberrant signaling
- Vascular protective strategies
The study of Notch Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bandyopadhyay S, et al. (2006). Age-dependent decrease of ADAM10 in the brain. Neurobiology of Aging.
- Van Hoecke A, et al. (2012). DLL3 as a therapeutic target in ALS. Nature.
- Alberi L, et al. (2013). Activity-induced Notch signaling in neurons. Nature Reviews Neuroscience.
- Saftighi M, et al. (2020). Notch signaling in Alzheimer's disease. Journal of Alzheimer's Disease.
- Joutel A, et al. (1996). Notch3 mutations in CADASIL. Nature.
- Lathia JD, et al. (2008). Notch in the nervous system. Nature Reviews Neurology.
- Chen MS, et al. (2000). Relationship between Notch and Aβ. Nature.
- Woo HN, et al. (2011). Notch and γ-secretase in neurodegeneration. Experimental Neurobiology.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
75% |
Overall Confidence: 36%